TY - JOUR
T1 - Immunological and translational key challenges in systemic lupus erythematosus
T2 - A symposium update
AU - Renaudineau, Yves
AU - Muller, Sylviane
AU - Hedrich, Christian M.
AU - Chauveau, Dominique
AU - Bellière, Julie
AU - De Almeida, Sébastien
AU - Damoiseaux, Jan
AU - Scherlinger, Marc
AU - Guery, Jean Charles
AU - Sailler, Laurent
AU - Bost, Chloé
N1 - Funding Information:
Authors are thankful to Dr. Wesley H. Brooks ( University of South Florida , USA ) and Gisèle Touzanne for editorial assistance. S.M. acknowledges the support of the French Centre National de la Recherche Scientifique ( CNRS ); the University of Strasbourg Institute for Advanced Study (USIAS); the ITI 2021–2028 program, University of Strasbourg-CNRS- Inserm , IdEx Unistra ( ANR-10-IDEX-0002 ) and SFRI ( STRAT’US project, ANR-20-SFRI-0012 ); the European Regional Development Fund of the European Union in the context of the INTERREG V Upper Rhine program; the FHU ARRIMAGE and the OMAGE project granted by Region Grand-Est of France and FEDER . S.M. also thanks the TRANSAUTOPHAGY COST Action ( CA15138 ) and the Club Francophone de l’Autophagie (CFATG).
Funding Information:
As reviewed by D. Chauveau, LN is associated with increased mortality and morbidity in SLE patients. Among a French cohort of 6439 SLE adult patients, clinical outcome at 6 years was associated with a distinct and important risk of end-stage renal disease (4.0%), cardiovascular event (14.4%), septic shock (6.3%), and death (9.6%) [61]. All these parameters are strongly associated with a chronic kidney disease at baseline, estimated with a glomerular filtration rate [eGFR] <60 ml/min/1.73m2, supporting that LN occurs in 30–60% of adults with SLE patients that represents a major risk factor particularly when associated with a proliferative glomerulonephritis (i.e. class III/IV +/- V). In the last two decades (Fig. 2), tremendous efforts have been achieved to improve renal prognosis in LN including a revised pathologic classification (ISN/RPS criteria), the recommendation to re-biopsy in order to appreciate renal remission, the availability of new biomarkers such as anti-C1q autoantibodies and the soluble urinary CD163 marker, guidelines dedicated to LN management and novel therapies, mostly biologics, with only a few showing clinically significant improvement (e.g. belimumab, voclosporin and obinutuzumab) [62–68]; Rovin et al., 2021; [69,70]. In spite of advances, the remission rate of LN remains unsatisfactory.Authors are thankful to Dr. Wesley H. Brooks (University of South Florida, USA) and Gisèle Touzanne for editorial assistance. S.M. acknowledges the support of the French Centre National de la Recherche Scientifique (CNRS); the University of Strasbourg Institute for Advanced Study (USIAS); the ITI 2021–2028 program, University of Strasbourg-CNRS-Inserm, IdEx Unistra (ANR-10-IDEX-0002) and SFRI (STRAT'US project, ANR-20-SFRI-0012); the European Regional Development Fund of the European Union in the context of the INTERREG V Upper Rhine program; the FHU ARRIMAGE and the OMAGE project granted by Region Grand-Est of France and FEDER. S.M. also thanks the TRANSAUTOPHAGY COST Action (CA15138) and the Club Francophone de l'Autophagie (CFATG).
Publisher Copyright:
© 2023
PY - 2023/1/1
Y1 - 2023/1/1
N2 - The first LBMR-Tim (Toulouse Referral Medical Laboratory of Immunology) symposium convened on December 16, 2022 in Toulouse, France to address challenging questions in systemic lupus erythematosus (SLE). Special focus was put on (i) the role played by genes, sex, TLR7, and platelets on SLE pathophysiology; (ii) autoantibodies, urinary proteins, and thrombocytopenia contribution at the time of diagnosis and during follow-up; (iii) neuropsychiatric involvement, vaccine response in the COVID-19 era, and lupus nephritis management at the clinical frontline; and (iv) therapeutic perspectives in patients with lupus nephritis and the unexpected adventure of the Lupuzor/P140 peptide. The multidisciplinary panel of experts further supports the concept that a global approach including basic sciences, translational research, clinical expertise, and therapeutic development have to be prioritized in order to better understand and then improve the management of this complex syndrome.
AB - The first LBMR-Tim (Toulouse Referral Medical Laboratory of Immunology) symposium convened on December 16, 2022 in Toulouse, France to address challenging questions in systemic lupus erythematosus (SLE). Special focus was put on (i) the role played by genes, sex, TLR7, and platelets on SLE pathophysiology; (ii) autoantibodies, urinary proteins, and thrombocytopenia contribution at the time of diagnosis and during follow-up; (iii) neuropsychiatric involvement, vaccine response in the COVID-19 era, and lupus nephritis management at the clinical frontline; and (iv) therapeutic perspectives in patients with lupus nephritis and the unexpected adventure of the Lupuzor/P140 peptide. The multidisciplinary panel of experts further supports the concept that a global approach including basic sciences, translational research, clinical expertise, and therapeutic development have to be prioritized in order to better understand and then improve the management of this complex syndrome.
KW - COVID-19
KW - Genetics
KW - Lupus nephritis
KW - Lupuzor
KW - Nervous system
KW - Platelets
KW - Systemic lupus erythematosus
KW - TLR7
KW - Vaccine
U2 - 10.1016/j.jtauto.2023.100199
DO - 10.1016/j.jtauto.2023.100199
M3 - Article
C2 - 37065621
SN - 2589-9090
VL - 6
JO - Journal of Translational Autoimmunity
JF - Journal of Translational Autoimmunity
IS - 1
M1 - 100199
ER -